Table 3. Primary and Secondary Outcomes.
| Outcome | Death or Disability at 3 mo | Hematoma Expansion at 24 h | ||||
|---|---|---|---|---|---|---|
| No. of Events | Crude RR (95% CI) | Adjusted RR (95% CI)a | No. of Events | Crude RR (95% CI) | Adjusted RR (95% CI)b | |
| CMB Status | ||||||
| No CMBs (n = 47) | 12/41 | 1 [Reference] | 1 [Reference] | 8/40 | 1 [Reference] | 1 [Reference] |
| CMBs (n = 120) | 34/116 | 1.00 (0.52-1.93) | 0.83 (0.40-1.71) | 21/104 | 1.01 (0.45-2.28) | 1.00 (0.42-2.39) |
| CMB Count | ||||||
| None (n = 47) | 12/41 | 1 [Reference] | 1 [Reference] | 8/40 | 1 [Reference] | 1 [Reference] |
| 1-2 (n = 45) | 11/44 | 0.85 (0.38-1.94) | 0.76 (0.33-1.76) | 8/40 | 1.00 (0.38-2.66) | 1.03 (0.37-2.87) |
| 3-10 (n = 42) | 13/42 | 1.06 (0.48-2.32) | 0.90 (0.37-2.24) | 7/38 | 0.92 (0.33-2.54) | 0.89 (0.30-2.64) |
| >10 (n = 33) | 10/30 | 1.14 (0.49-2.64) | 0.90 (0.34-2.42) | 6/26 | 1.15 (0.40-3.33) | 1.11 (0.36-3.44) |
| CMB Topography | ||||||
| None (n = 47) | 12/41 | 1 [Reference] | 1 [Reference] | 8/40 | 1 [Reference] | 1 [Reference] |
| Strictly lobar (n = 30) | 9/30 | 1.03 (0.43-2.43) | 0.90 (0.36-2.28) | 7/26 | 1.35 (0.49-3.71) | 1.15 (0.38-3.48) |
| Strictly deep (n = 34) | 8/34 | 0.80 (0.33-1.97) | 0.74 (0.29-1.91) | 6/31 | 0.97 (0.34-2.79) | 1.15 (0.39-3.45) |
| Mixed (n = 56) | 17/52 | 1.12 (0.53-2.34) | 0.85 (0.34-2.08) | 8/47 | 0.85 (0.32-2.27) | 0.83 (0.29-2.34) |
Abbreviations: CMBs, cerebral microbleeds; RR, relative risk.
a
Multivariable analysis adjusting for age, systolic blood pressure at initial presentation, baseline Glasgow Coma Scale score, assigned treatment group, the presence or absence of intraventricular hemorrhage at baseline, Fazekas scale total score, and estimated glomerular filtration rate.
b
Multivariable analysis adjusting for age, assigned treatment group, Fazekas scale total score, and time from onset to baseline computed tomography.